Angiotensin II receptor blockers (ARBs) with a mechanism of inhibiting the binding of angiotensin II receptors, which are involved in an increase in blood pressure, are effective in reducing the incidence of epilepsy, a new study has found.
The results of a study on the association between ARB treatment and epilepsy incidence in hypertensive patients conducted by Corinna Doege and others at the Bremen Central Hospital in Germany were published in the international journal JAMA Neurology on the 17th (doi:10.1001/jamaneurol.2022.3413).
Arterial hypertension is known to be associated with an increased incidence of epilepsy. In fact, it has been reported that ARB treatment can suppress epileptic seizures in animal experiments.
The researchers embarked on a cohort analysis to determine whether the animal test results could be replicated in human clinical trials.
The study obtained data from the database (IQVIA) for patients over 18 years of age with hypertension and prescribing at least 1 antihypertensive medication.
In the data, a total of 168,612 patients were selected through propensity score matching, excluding patients diagnosed with epilepsy before and after analysis among 1,553,875 patients who were prescribed at least one antihypertensive drug.
Among the four antihypertensive drug classes, patients treated with beta-blockers, ARBs, angiotensin-converting enzyme inhibitors, and calcium channel blockers were classified using propensity scores and the incidence of epilepsy for each component was investigated.
For each antihypertensive drug, 42,153 patients were assigned. The mean age of the patients was 62.3 years, and 51.4% were female.
As a result of the analysis, the incidence of epilepsy within 5 years was the lowest in patients treated with ARB (0.27% at 1 year, 0.63% at 3 years, 0.99% at 5 years). 0.38%, 0.93%, and 1.48%.
The relative risk reduction of epilepsy in the ARB-treated group was reduced by 23% compared to the other drug-treated group (HR 0.77).
“In this cohort study of hypertensive patients, ARB treatment was associated with a significant reduction in the incidence of epilepsy,” the researchers said. suggestive,” he added.